<DOC>
	<DOCNO>NCT03081143</DOCNO>
	<brief_summary>This clinical trial evaluate whether beneficial term prolongation survival combine FOLFIRI ( standard treatment ) ramucirumab compare standard treatment ramucirumab plus paclitaxel patient advance gastric cancer failure one prior line palliative chemotherapy . This trial aim investigate efficacy safety ramucirumab plus FOLFIRI ( investigational arm A ) compare paclitaxel plus ramucirumab ( control arm B ) .</brief_summary>
	<brief_title>Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel Patients With Advanced Metastatic Gastric Cancer , Who Failed One Prior Line Palliative Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Signed write informed consent 2 . Male female ≥ 18 year age ; Patients reproductive age must willing use adequate contraception study 3 month end ramucirumab treatment ( appropriate contraception define surgical sterilization ( e.g . bilateral tubal ligation , vasectomy ) , hormonal contraception ( implantable , patch , oral ) , doublebarrier method ( double combination : IUD , male female condom spermicidal gel , diaphragm , sponge , cervical cap ) ) . Female patient childbearing potential need negative pregnancy test within 7 day study start . 3 . Histologically proven gastric adenocarcinoma include adenocarcinoma esophagogastric junction 4 . Metastatic locally advance disease , amenable potentially curative resection 5 . Documented objective radiological clinical disease progression within 6 month last dose firstline platinum fluoropyrimidine doublet without anthracycline docetaxel . Neoadjuvant/adjuvant treatment count unless progression occur &lt; 6 month completion treatment.In case neoadjuvant/adjuvant treatment count one line . 6 . Measurable nonmeasurable evaluable disease 7 . ECOG performance status 01 8 . Life expectancy &gt; 12 week 9 . Adequate hematological , hepatic renal function : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L Hemoglobin ≥9 g/dL ( 5.58 mmol/L ) Total bilirubin ≤ 1.5 time upper normal limit ( UNL ) AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 x UNL absence liver metastasis , ≤ 5 x UNL presence liver metastases ; AP ≤ 5 x UNL Serum creatinine ≤ 1.5 x upper limit normal , creatinine clearance ( measure via 24hour urine collection ) ≥40 mL/minute ( , serum creatinine &gt; 1.5 time ULN , 24hour urine collection calculate creatinine clearance must perform ) Urinary protein ≤1+ dipstick routine urinalysis ( UA ; urine dipstick routine analysis ≥2+ , 24hour urine collection protein must demonstrate &lt; 1000 mg protein 24 hour allow participation protocol ) Adequate coagulation function define International Normalized Ratio ( INR ) ≤ 1.5 , partial thromboplastin time ( PTT ) ≤ 5 second ULN ( unless receive anticoagulation therapy ) . Patients receive warfarin/ phenprocoumon must switch low molecular weight heparin achieve stable coagulation profile prior first dose protocol therapy . 10 . Ability comply schedule assessment management toxicity 1 . Other tumor type adenocarcinoma ( e.g . leiomyosarcoma , lymphoma ) second cancer except patient squamous basal cell carcinoma skin carcinoma situ cervix effectively treat . Patients curatively treat diseasefree least 5 year discuss sponsor inclusion 2 . Squamous gastric cancer 3 . Concurrent chronic systemic immune therapy , chemotherapy , hormone therapy indicate study protocol 4 . Previous therapy paclitaxel FOLFIRI 5 . Current treatment anticancer therapy ≤ 2 week prior study treatment start unless rapidly progress disease measure 6 . Concurrent treatment anticancer therapy 7 . Previous exposure VEGF VEGFR inhibitor antiangiogenic agent , prior enrolment study 8 . Patient undergone major surgery within 28 day prior first dose protocol therapy , minor surgery/subcutaneous venous access device placement within 7 day prior first dose protocol therapy . The patient elective plan major surgery perform course clinical trial 9 . Grade 34 GI bleeding within 3 month prior enrollment 10 . History deep vein thrombosis ( DVT ) , pulmonary embolism ( PE ) , significant thromboembolism ( venous port catheter thrombosis superficial venous thrombosis consider `` significant '' ) 3 month prior first dose protocol therapy 11 . Cirrhosis level ChildPugh B ( bad ) cirrhosis ( degree ) history hepatic encephalopathy clinically meaningful ascites result cirrhosis . Clinically meaningful ascites define ascites cirrhosis require diuretic paracentesis . 12 . Known brain leptomeningeal metastases 13 . Known allergic/ hypersensitivity reaction component treatment 14 . Contraindications use atropine 15 . Other serious illness medical condition within last 12 month prior study drug administration 16 . Any arterial thromboembolic event , include limited myocardial infarction , transient ischemic attack , cerebrovascular accident , unstable angina , within 6 month prior first dose protocol 17 . The patient uncontrolled poorlycontrolled hypertension ( &gt; 160 mmHg systolic &gt; 100 mmHg diastolic &gt; 4 week ) despite standard medical management 18 . Active uncontrolled infection 19 . Current history chronic diarrhea 20 . Active disseminate intravascular coagulation 21 . Any serious concomitant disease medical condition judgment investigator render subject high risk treatment complication reduce probability assess clinical effect 22 . Known Dihydropyrimidine dehydrogenase ( DPD ) deficiency 23 . Prior history GI perforation/fistula ( within 6 month first dose protocol therapy ) risk factor perforation . 24 . Serious nonhealing wound , ulcer , bone fracture within 28 day prior first dose protocol therapy 25 . The patient receive chronic antiplatelet therapy , include aspirin , nonsteroidal antiinflammatory drug ( NSAIDs , include ibuprofen , naproxen , others ) , dipyridamole clopidogrel , similar agent . Oncedaily aspirin use ( maximum dose 325 mg/day ) permit 26 . Concurrent treatment experimental drug participation another clinical trial investigational drug within 30 day prior treatment start 27 . Known drug abuse/ alcohol abuse 28 . Lack resolution toxic effect ( exclude alopecia ) prior chemotherapy , prior radiotherapy surgical procedure National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) grade &lt; 1 . Note : Neuropathy due prior chemotherapy allow &gt; NCI Grade II accord CTCAE version 4.03 29 . Subject pregnant breast feeding , plan become pregnant within 3 month end treatment 30 . Subject ( male female ) willing use highly effective method contraception ( per institutional standard ) treatment 3 month ( male female ) end treatment 31 . Patients known HER 2 positive Cancer treat already HER 2 target agent . 32 . Patients psychiatric illness patient imprison work institution treat physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>